Review

Next-Generation Liposomal Drug Delivery Systems: Core Principles, Innovations, and Targeting Strategies

ASHUTOSH SENGAR *

Posted Date: 27 January 2025

doi: 10.20944/preprints202501.1875.v1

Keywords: liposomal drug delivery; nanoparticles; controlled release; surface-modified liposomes; herbal medicines and liposomes

Review

Next-Generation Liposomal Drug Delivery Systems: Core Principles, Innovations, and Targeting Strategies

Ashutosh Sengar

Assistant Professor, Dept. of Pharmaceutics, Smt. Vidyawati College of Pharmacy, Smt. Vidyawati Group of Institutions, Jhansi; ashutoshsengar26567@gmail.com

Abstract: Modern therapeutics have come to focus attention on liposomal drug delivery systems as innovative and effective vehicles for targeted drug delivery. Lipid-based vesicles may encapsulate drugs that are either hydrophilic or hydrophobic, bringing about unique advantages such as improved bioavailability, protection of the encapsulated drug from degradation, and the potential to provide controlled and sustained release. Liposomal systems have also been formulated to produce different kinds of formulations including surface-modified liposomes, stealth liposomes, and cationic liposomes; each has a different therapeutic application. The introduction of liposomal systems into some newly emerging technologies like nanotechnology helps target drugs better and personalize treatment protocols. This review on the basics in drug delivery as liposomes that covers structural and compositional aspects, mechanisms associated with the encapsulation, and release, also incorporates new developments in the formulations of liposomal, comparisons between liposomes, and other types of delivery systems, and possibilities in the integration of herbal medicines, such as the Tribulus terrestris to enhance therapeutic performance. Further discussed issues are scaling up, stability, and regulatory challenges of liposomal formulation, besides the opportunities for further advancements of liposomal technology in future pharmaceutical applications. Thus, it is expected that the role of liposomes in personalized medicine will continue to increase significantly with a good prospect for the creation of safer, more efficient, and targeted therapies for most diseases.

Keywords: liposomal drug delivery; nanoparticles; controlled release; surface-modified liposomes; herbal medicines and liposomes

---

Table of Contents

 doi:10.20944/preprints202501.1875.v1

- Formulation of mouth-dissolving films for liposomal drug delivery
- Chewable and effervescent tablet integration for liposomal systems

5. Comparative Analysis with Other Drug Delivery Systems

- Nanoparticles vs. liposomal systems: A comparative analysis
- Alternative vesicular systems: Proniosomes and effervescent tablets

6. Herbal Approaches and Liposomal Integration

- Advances in herbal treatments and liposome compatibility (focus on Tribulus terrestris)
- Applications of herbal medicines with liposomal formulations for targeted delivery

7. Challenges and Opportunities

- Scalability, stability, and regulatory challenges
- Opportunities for advancing liposomal technology

1. Introduction to Liposomal Drug Delivery Systems

The advent of liposomal drug delivery systems transformed pharmaceutical sciences to introduce a new approach in terms of the efficacy and safety of therapeutic agents. Lipid bilayer encapsulated drug delivery systems bear several advantages with regard to delivering drugs through bioavailability, targeting, and much reduced systemic toxicity. The liposomes can be tuned to carry very wide-ranging molecules of drugs-from hydrophilic to hydrophobic compounds - and thus offer versatile and efficient drug carriers [1,2].

Apart from their efficiency in drug delivery, liposomal systems are important since they ensure controlled release; hence, they produce relatively fewer side effects and proper actions of drugs to the body. With their compatibility, biodegradable nature, non-toxicity, and targeting at certain tissues or cells, they have broad applications in areas such as cancer therapy, vaccines, and gene delivery [2]. This diversity within the liposomal formulation allowed for various surface modifications for enhanced stability and specificity toward targeting of disease sites. This has come to be an ever-expanding field of research intended to further modify liposomal technology for personalized medicine and advanced drug delivery [1].

1.1. Historical Evolution and Rationale for Developing Liposomal Carriers

Concept on liposomal drug delivery systems Liposomes were considered to be as a potential carrier of drugs ever since the very beginning of this concept in 1960s; hence, an early study into biocompatibility to encapsulate either hydrophilic or hydrophobic drugs spurring the discovery of liposomal formulations. Basic idea behind forming liposomal drug delivery systems derives from the motivation by overcoming the deficits of traditional drugs. Before liposomes, drugs were administrated systematically. Problems associated with poor bioavailability, high toxicity, and poor tissue targeting of the disease developed. Liposomes represented a rather bright possibility since drugs could be formulated inside a bilayer membrane, thus shielding them from premature degradation, enhancing absorption, and providing time-release over time [3].

Advances in lipid chemistry and biopharmaceutical research have profoundly influenced the development of liposomal systems. One significant breakthrough occurred during the 1990s, known as "stealth" liposomes, that were PEGylated for immune evasion, thus enhancing longer circulation times within the blood vessel and delivering them to a desired organ or tissue, often targeting tumor sites. Continuous development of liposomal formulations and understanding of their interaction with the body have since positioned liposomes as one of the most promising technologies in drug delivery [3].

 doi:10.20944/preprints202501.1875.v1

1.2. Introduction to Nanoparticles in Drug Delivery and Their Comparison with Liposomes

A nanoparticle is a new class of emerging drug delivery systems, which are getting much attention in the better precision of drug delivery.

The structures of nanoparticles are in the form of solid lipid nanoparticles (SLNs), polymeric nanoparticles, and liposomes.

Although both nanoparticles and liposomes share the potential advantage of size at the nanoscale dimension, which allows them to circulate with greater ease and penetrate tissues while in the blood, liposomes are unique because their lipid bilayer can encapsulate both hydrophobic and hydrophilic drugs.

Unlike the conventional nanoparticles, liposomes encapsulate drugs uniquely through their phospholipid bilayer that simulates biological membranes.

Liposomes can therefore interact better with cell membranes and thus improve the intended tissue-specific release of drugs. In addition, the surface properties of liposomes can be modified to improve their specificity to any particular cell type, which is one of the major strengths of liposomes as compared to other types of nanoparticles, which might not present the same options of selectivity in targeting [4].

Relative higher biocompatibility concerning stability compared with some of the formulations including nanoparticle liposomes, hence makes the system even more reliable with long-term therapeutics.

Apart from the size advantages of nanoparticles, liposomes present another advantage when it comes to delivering biologically active molecules, such as proteins, peptides, and nucleic acids.

Generally, better therapeutic efficacy in overall terms comes from the protective functions of liposomes that prevent easily degradable drugs by enzymes while maintaining their prolonged release.

Being multifaceted regarding size, biocompatibility, and drugs to be encapsulated, liposomes have proven to be the essential tool of modern drug delivery research [4].

Table 1. Comparison of Nanoparticles and Liposomes in Drug Delivery [4].

No.	Nomenclature	Description
1	**Nanoparticles**	Emerging drug delivery systems that provide better precision in drug delivery. Nanoparticles include solid lipid nanoparticles (SLNs), polymeric nanoparticles, and liposomes.
2	**Liposomes**	A unique type of nanoparticle with a lipid bilayer capable of encapsulating both hydrophobic and hydrophilic drugs, mimicking biological membranes.
3	**Comparison of Nanoparticles and Liposomes**	While both operate at nanoscale dimensions for better circulation and tissue penetration, liposomes uniquely encapsulate drugs using a phospholipid bilayer, offering better tissue-specific drug release and interaction with cell membranes.
4	**Modifiable Surface Properties**	Liposomes' surface properties can be altered for higher specificity to target particular cell types, a feature not commonly shared by other nanoparticles.
5	**Biocompatibility and Stability**	Liposomes offer higher biocompatibility and stability compared to some formulations, making them reliable for long-term therapeutics.
6	**Delivery of Biologically Active Molecules**	Liposomes are better suited for delivering proteins, peptides, and nucleic acids. Their protective lipid bilayer prevents enzyme degradation and maintains prolonged drug release, enhancing therapeutic efficacy.

 doi:10.20944/preprints202501.1875.v1

7	**Multifaceted Benefits**	Liposomes are versatile due to their size, biocompatibility, and capability to encapsulate a wide variety of drugs. They have become a critical tool in modern drug delivery research.

2. Structure and Composition of Liposomes

Liposomal drug delivery systems are composed mainly of lipid molecules or other arrangements in a bilayer structure, essential for their functionality as pharmaceutical carriers. A rather high plasticity is obtained by creating a liposomal structure that imitates the natural biological membranes, by encapsulating and delivering a wide range of therapeutic substances.

2.1. Phospholipid Bilayer: Components and Properties

Liposomes, basically, are a bilayered structure composed of phospholipid. These are amphiphilic compounds, which have head and tail portions. The compound is hydrophilic; so, the head naturally tends to interact with an aqueous environment. The tail, being hydrophobic, means it normally avoids a water environment. That kind of a structure assembles into a bilayer. The bilayer can be used to form a semi-permeable membrane that traps the interior and bilayer of hydrophilic and hydrophobic compounds.

Major factors determining the general stability, permeability, and fluidity of the liposome are the properties of the phospholipids, which include chain length, saturation, and head group charge. The unsaturated fatty acid chains introduce some extra flexibility and fluidity to the bilayer-a feature proved to influence drug release rates. On the other hand, saturated fatty acid chains enhance the rigidity and stability of the bilayer, which is desirable for certain applications that require longer circulation times [2].

In addition to these primary lipids, composing liposomes, there may be some sort of additives whereby cholesterol is supplemented to the bilayer to support stabilization of membranes and minimize leakage of encapsulated drugs into the surroundings. In fact, cholesterol interacts with the phospholipids forming the liposomal membrane, reducing its membrane permeability and therefore increasing the resistance of the vesicle to extrinsic stress factors such as temperature fluctuation or a pH change. This is an important factor because liposomes have to remain intact for as long as they circulate in the blood stream or travel through the body's biological barriers [2].

2.2. Key Types of Liposomes

There are several main kinds of liposomes, which serve to solve some specific problems that exist in the drug delivery area. The three most common are conventional liposomes, stealth liposomes, and cationic liposomes. The differences in them have significant characteristics that determine performance and application areas in pharmaceutical therapy.

2.2.1. Conventional Liposomes

Conventional liposomes are the simplest and most common type of liposomal carriers. These liposomes contain a bilayer of lipids, capable of entrapping hydrophilic and hydrophobic drugs. Typically, such liposomes contain phospholipids, for example, phosphatidylcholine, cholesterol, and other materials that have a number of drug delivery applications. However, the regular liposomes usually are recognized early by the immune system and have to be quickly cleared from the bloodstream, reducing their efficiency for certain therapeutic application contexts. Although they are already used very intensely in many experimental studies and certain applications for therapy [8].

2.2.2. Stealth Liposomes (PEGylated Liposomes)

Stealth liposomes or PEGylated liposomes are constructed such that the objective of them going long enough for the residence of these in circulation is prevented to evade the immunity system. The polymer coats the outer coat of the liposome - it's water-soluble and called polyethylene glycol. The

 doi:10.20944/preprints202501.1875.v1

modification prevents recognition and clearance by the mononuclear phagocyte system and thus makes it possible for such liposomes to stay in circulation longer and attain target sites more efficiently. This becomes particularly useful in delivering chemotherapeutic agents where prolonged systemic circulation is vital to maximize the therapeutic outcome [8].

2.2.3. Cationic Liposomes

Another notable category is that of cationic liposomes, which has a positive surface charge. Overall, they are produced by cationic lipids that have electrostatic attraction to negatively charged molecules such as DNA or RNA. Due to their positive nature, cationic liposomes are easily applicable in gene delivery, as it can easily combine with nucleic acids and enter the cells. Additionally, being cationic in nature, these liposomes can fuse well with the cell membranes that carry a negative charge, hence promoting the transfection efficiency of the genetic material being encapsulated. However, such a positive charge also leads to increased toxicity, which must be controlled for practical applications in medicine [8].

Different kinds of liposomes hold different potential depending upon their application and with the opportunity of modifying their surface as well as the composition, with the aid of which different hurdles like immune evasion or controlled release could be covered through targeted delivery. The elaboration of such particular liposomal systems has indeed enormously expanded their ranges of possible application in therapeutical fields along with diagnosis as well for curing cancer through gene therapy as also for delivering vaccine.

3. Mechanisms of Drug Encapsulation and Release

The liposomal drug delivery system is essentially designed to encapsulate a broad spectrum of therapeutic agents, which ensures that the agent would be safely and effectively delivered to the sites in the body where it needs to be located. Encapsulation and controlled release of the drug, therefore, become very important factors determining stability, bioavailability, and efficacy of the drug in its formulation.

3.1. Techniques for Drug Loading in Liposomes

The process of loading drugs into liposomes can be achieved through various methods. The choice of method is that depending on the physicochemical characteristics of the drug and the desired release characteristics, this technique ensures that active pharmaceutical ingredients (APIs) are efficiently encapsulated in the liposomal structure, while controlling the drug release profile.

3.1.1. Passive Loading (Thin-Film Hydration Method)

The most common method of drug loading is the thin-film hydration method. This involves dissolving lipids in organic solvents, which is then evaporated to give a thin lipid film. The aqueous phase is the drug that hydrates the film. This way, hydrophilic drugs are encapsulated within the aqueous core of the liposome. On the other hand, hydrophobic drugs are incorporated into the lipid bilayer [11]. It is simple and inexpensive and broadly applicable, though it may not always yield the highest drug encapsulation efficiency.

3.1.2. Active Loading (Ion-Gradient Method)

More effective drug encapsulation, particularly with drugs having poor solubility, is made possible through the use of active loading techniques. The ion-gradient technique generates an internal concentration gradient using an ammonium sulfate or a similar ion that causes passive influx into the liposomes by drugs. With the gradient now inside, drugs become concentrated inside the liposome, making drug loading greater. This technique is very useful for the encapsulation of weakly acidic or basic drugs and offers a more controlled and higher drug loading than passive methods [11,12].

 doi:10.20944/preprints202501.1875.v1

3.1.3. Reverse-Phase Evaporation Method (REV)

The drug is dissolved in an organic solvent, which, by forming a reverse-phase system with lipids, encapsulates the liposomal vesicles. This leads to the reduction of the solvent under reduced pressure. The evaporation under reduced pressure, employing a variety of methods and apparatuses, has made the REV highly efficient for the loading of hydrophobic as well as hydrophilic drugs with high encapsulation efficiency, particularly with high-molecular-weight compounds [11].

3.1.4. Freeze-Thaw Method

Freeze-thaw method entails cycles of repeated freezing and subsequent thawing in the presence of the drug solution in the lipids. Freeze-thaw ultimately leads to a formation of multiple bilayer lipid vesicles trapping the drug. Despite having a much lower capacity for incorporating drugs, it is useful to entrap drug amounts larger than those feasible by other loading methods. For this reason, it is heavily utilized in large-scale production for clinical use liposomes.

Table 2. Techniques for Drug Loading in Liposomes.

No.	Nomenclature	Description	Citations
1	**Passive Loading (Thin-Film Hydration Method)**	A common and cost-effective technique involving the dissolution of lipids in organic solvents, which are then evaporated to form a thin lipid film. The aqueous drug solution hydrates the film, encapsulating hydrophilic drugs in the aqueous core and hydrophobic drugs in the lipid bilayer.	[11]
2	**Active Loading (Ion-Gradient Method)**	A method using ion gradients (e.g., ammonium sulfate) to drive drugs into liposomes. Particularly effective for weakly acidic or basic drugs, this technique offers higher encapsulation efficiency and controlled drug loading compared to passive methods.	[11,12]
3	**Reverse-Phase Evaporation Method (REV)**	The drug is dissolved in an organic solvent and forms a reverse-phase system with lipids. After reducing the solvent under pressure, this method achieves high encapsulation efficiency for hydrophilic and hydrophobic drugs, especially high-molecular-weight compounds.	[11]
4	**Freeze-Thaw Method**	Involves repeated cycles of freezing and thawing in the presence of a drug solution and lipids. This method creates multilamellar vesicles and is commonly used for large-scale production due to its ability to entrap larger amounts of drugs than other methods.	[11]

3.2. Controlled Release Mechanisms and Influencing Factors

After encapsulating the drug inside the liposome, it becomes challenging to control the drug's release at the site of action. The profile for the release of the drug varies depending on many composition-related factors to the structure of the liposome and the environment in which the drug is delivered. The critical mechanisms of controlled drug release from liposomes include:

3.2.1. Diffusion-Controlled Release

This form of release depends on diffusion because the drug can be released either passively, from the aqueous core into the lipid bilayer or by passive diffusion from the liposome. The principal factors controlling diffusion-controlled release include solubility of the drug, lipid composition of the bilayer, and the thickness of the membrane. The normal rate of drug release depends on the gradient

 doi:10.20944/preprints202501.1875.v1

concentration of drugs between the liposome's inner side and its exterior environment by drug diffusion from regions of higher concentrations to regions of lower concentrations [13].

3.2.2. pH-Sensitive Release

Liposomes can even be designed such that the releasing of drugs becomes pH dependent and can target, for example specific tissues such as tumors or the gastro-intestinal region where the local pH environment drastically differs from healthy tissues. The pH-sensitive release mechanism is realized through the employment of pH-sensitive materials, for example, amine-containing lipids, that undergo protonation at acidic pH levels, thus destabilizing the liposomal membrane and causing the encapsulated drug to be released. Such a mechanism can be very beneficial for targeted chemotherapy drug delivery, as cancerous cells often maintain lower pH values [13].

3.2.3. Thermo-Sensitive Release

Another method with controlled release of a drug is the temperature-sensitive liposomes. Here, these liposomes are prepared with the help of thermosensitive lipids, which will undergo a phase transition at given temperatures. Thus, for example, at body temperature, these liposomes may retain their structure and contain the drug, but once heated to higher temperatures (in the targeted area of disease), the membrane of the liposome will undergo a phase change that will increase membrane permeability to allow drug release. This approach is generally used for the localized delivery of drugs in applications such as the treatment of cancer, in which external heat is applied to facilitate release at the tumor site [13].

3.2.4. Enzyme-Mediated Release

Enzyme-sensitive liposomes are drug delivery systems designed to release their drug when they encounter specific enzymes of interest at the targeted site. They are formed from either lipids or polymers that have enzymatic sensitivity to degradation caused by the body's own enzymes, such as phospholipases, proteases, or esterases. For instance, in the majority of pathological conditions, enzymes are highly upregulated, hence, the release of the drug at the targeted site can be precisely very high, for example in some cancers, and inflammation [13].

3.2.5. Electrostatic and Surface Modifications

Also, surface modification with charged groups or targeting ligands may even modulate the release mechanism by liposome. Cationic liposomes may interact with the negatively charged membranes of the cell directly to enable uptake by cells and subsequent release inside the cell to deliver the drugs. In addition, liposomes engineered with specific targeting ligands such as antibodies or peptides can selectively bind to the receptors of the target cells for specific drug delivery only at the site of disease in such a manner that systemic side effects are minimized [11].

4. Innovations in Liposomal Formulations

Liposomal drug delivery systems have become significantly developed within the last couple of decades. Many innovations, designed to make them more effective, targeted at the site of action, and patient-compliant, have transformed the landscape in this field. Advances in techniques for liposome formulation not only improved the therapeutic outcome but also permitted the development of new drug delivery modalities: personalized medicine, patient-friendly dosage forms, etc. Some of the innovations that could be documented as most significant for liposomal formulations concern surface modifications, personalized care strategies, and new oral delivery systems.

 doi:10.20944/preprints202501.1875.v1

4.1. Development of Surface-Modified Liposomes (Ligands, PEGylation)

Surface-modified liposomes are the most exciting innovation in drug delivery via liposomes to prolong circulation times, deliver these systems to specific tissues, and improve the effectiveness of drug delivery. PEGylation and insertion of targeting ligands are the most used approaches for this purpose.

4.1.1. PEGylation

The polymer of polyethylene glycol is normally applied for modification on the outer surface of the liposome. PEGylation would attach the PEG chains to the outer surface of the liposome; therefore, making it perform some very important functions. For example, the attachment masks the liposome from the immune system and thereby diminishes the immune recognition and its MPS clearance drastically. This leads to a longer circulation time, which eventually improves the delivery of liposomes to their specific sites. Pegylation also prevents the aggregation of liposomes and hence makes them stable and homogeneous in solution [11].

4.1.2. Targeting Ligands

A highly critical innovation is that of targeting ligands conjugated with the surface of liposomes. Ligands including antibodies, peptides, or small molecules can be conjugated to the surface of liposomes for selective binding of such liposomes with specific receptors or antigens expressed on target cells or tissues. The targeting approach would increase selectivity and specificity in drug delivery, reducing unwanted off-targeting while ensuring greater therapeutic potency of the drug inside the liposomes. One of the applications of these is antibody-targeted liposomes, which were used in cancer therapy to selectively deliver chemotherapy drugs to tumor cells, and peptide-based targeting for the delivery of gene therapy agents [11].

Together, surface-modified liposomes have revolutionized drug delivery, thereby opening avenues to even more effective treatment regimens with fewer side effects and much better patient outcomes.

4.2. Personalized Care with Nanotechnology-Based Targeting Strategies

Nanotechnology has been increasingly applied in drug delivery, which opened the way to great advancements of personalized medicine; if targeted formulations are liposomes, then therapy could be fine-tuned toward the needs of individual patients while maximizing therapeutic effect and minimizing toxic side effects.

This directly targets drugs at the site of disease in a bid to enhance the efficacy of treatment. For example, with chemotherapy, liposomes modified with ligands targeting specific tumor-specific markers would deliver the therapeutic drug only to those cells while excluding it from acting on normal tissue. The growing need for these approaches is increasing with the emerging era of personalized care, especially with treatments adapted to individualized genetic profiles as well as distinctive characteristics of a patient's specific disease in other unique factors distinctive to each one. The prospects for more effective and targeted therapeutic regimens with liposomes in nanocarriers, applications in gene therapy, and the targeting of genes by means of biomarkers have been widely enhanced [10].

Another new term that has recently emerged is theranostic liposomes, which may marry therapeutic and diagnostic functions, ending up as powerful tools in personalized care. The delivery of drugs can be accompanied by the concomitant real-time imaging of the site of the treatment through theranostic liposomes. Therefore, clinicians can monitor in real-time how the therapy is working, and they may take necessary adjustments accordingly.

 doi:10.20944/preprints202501.1875.v1

4.3. Formulation of Mouth-Dissolving Films for Liposomal Drug Delivery

Mouth dissolving films for liposomal systems is another innovative approach of drug delivery through the oral route. These are film formulations that dissolve rapidly in the mouth; they replace the conventional oral dosage forms such as tablets and capsules. Mouth-dissolving films have all these advantages: fast onset of action, ease of administration, and improved patient compliance especially in patients with dysphagia or conditions that alter the ordinary process of swallowing [6].

Liposomes are incorporated into mouth-dissolving films especially for drugs with poor solubility or poor bioavailability. Such drugs can be encapsulated by liposomes to increase their absorption via the oral mucosa while avoiding the gastrointestinal tract and hence improve the drug's bioavailability. In addition, it can protect drugs from degradation through the acidic gastric environment, providing the drug in the active form as it reaches its target site. The combination of liposomes with mouth-dissolving films is thereby a promising formulation strategy for administering a wide spectrum of drugs-including pain and antihypertensive medicines and antidepressants [6].

Table 3. Formulation of Mouth-Dissolving Films for Liposomal Drug Delivery.

No.	Nomenclature	Description
1	**Mouth-Dissolving Films (MDFs)**	Innovative oral drug delivery systems that dissolve quickly in the mouth, replacing tablets and capsules. Advantages include fast onset of action, ease of administration, and improved patient compliance, especially for dysphagia patients.
2	**Incorporation of Liposomes into MDFs**	Liposomes encapsulate poorly soluble or bioavailable drugs to enhance their absorption through the oral mucosa, bypassing the gastrointestinal tract and avoiding drug degradation in the acidic gastric environment.
3	**Advantages of Liposomal MDFs**	Improved bioavailability, protection from gastric degradation, and efficient delivery of active drugs directly to the target site.
4	**Applications of Liposomal MDFs**	Useful for a broad spectrum of drugs, including pain relievers, antihypertensive medications, and antidepressants.

4.4. Chewable and Effervescent Tablet Integration for Liposomal Systems

One other new trend in the formulation of liposomes is incorporation of liposomes into the chewable tablets and effervescent tablets that are greatly accepted by patients for its usage in pediatric and geriatric patients. Chewable tablets are prepared in such way that these can easily dissolve in the mouth. The effervescent tablets produce gas when they come into contact with water; there will be a fizzing of the solution which can enhance the drug dissolution and absorption [5], [7].

These tablet types can contain liposomal formulations, which can provide controlled drug release and improved drug bioavailability, especially for poorly water-soluble drugs. The effervescent tablets give rapid disintegration and dissolution, ensuring that the drug is absorbed quickly and efficiently, and improving the taste masking of unpleasant-tasting drugs. This is particularly useful for drugs administered to children or patients who are sensitive to the taste of medication. Moreover, incorporating liposomal systems into effervescent and chewable tablets may protect drugs from degradation in the gastric environment and thus improve their bioavailability by encouraging absorption through the gastrointestinal tract [5], [7].

With the combination of novel oral dosage forms and liposomal encapsulation benefits, innovative liposomal systems offer a tremendous scope for bettering patient adherence and the therapeutic efficacy of drug treatments.

5. Comparative Analysis with Other Drug Delivery Systems

Liposomal systems are very versatile and effective; however, they form part of a much larger landscape of drug delivery technologies. Other systems such as nanoparticles and alternative

 doi:10.20944/preprints202501.1875.v1

vesicular systems have been pursued for improvement in drug delivery efficiency. This section will present comparative analysis of the liposomes against such systems and give emphasis to how the superior advantages that individual systems offer with their challenges.

5.1. Nanoparticles vs. Liposomal Systems: A Comparative Analysis

The most studied drug delivery candidates are nanoparticles and liposomes, which differ in terms of structure, drug release, and biological interaction. Nanoparticles are made up of polymers, metals, or lipids and range from 1 to 100 nm in size. Their surface properties can be engineered to increase the efficiency of the drug-targeting process, and they exhibit improved cell penetration and are more stable than liposomes. Nano particle can be engineered to carry most of the varieties of drugs: hydrophilic or hydrophobic, for its delivery to all target locations which can be treated by both of the approaches: passive and active targeting [4].

A liposome, though, has a specific structure—a bilayer phospholipid membrane—but can still encapsulate both hydrophilic and hydrophobic drugs inside it, hence providing more flexibility in drug loading. Liposomes can also be biocompatible and biodegradable to make them even safer for the long term. Due to their ability to protect drugs from degradation and provide control release, they have positioned themselves as excellent tools in the treatment of diseases and anticancer and gene therapy treatment. Contrary to this, with the decreased size of nanoparticles, it can easily cross the biological barriers such as the blood-brain barrier, and therefore shows a higher accurate targeting ability of the specific tissues [3].

Finally, the decision has to be made between nanoparticles and liposomes, which depends on the drug. It depends on what kind of drug has to be delivered, what profile is required, and what kind of disease it has to treat. Liposomes possess some inherent property of controlled and sustained release; however, it may be that the particles might be better at targeting properties and cellular uptake.

Table 4. Nanoparticles vs. Liposomal Systems: A Comparative Analysis.

No.	Nomenclature	Description
1	**Nanoparticles**	Composed of polymers, metals, or lipids; size ranges from 1 to 100 nm. Surface properties can be engineered to improve drug targeting, offering enhanced stability, cell penetration, and delivery of hydrophilic and hydrophobic drugs.
2	**Liposomal Systems**	Consist of a bilayer phospholipid membrane that encapsulates both hydrophilic and hydrophobic drugs. Liposomes are biocompatible, biodegradable, and provide controlled and sustained drug release, making them excellent for long-term use.
3	**Drug Loading and Delivery**	Nanoparticles are highly versatile and can carry a wide variety of drugs for both passive and active targeting. Liposomes, while versatile, excel in encapsulation flexibility, drug protection, and controlled release.
4	**Targeting Ability and Barrier Crossing**	Nanoparticles, due to their smaller size, can easily cross biological barriers like the blood-brain barrier, allowing more accurate tissue targeting. Liposomes are more suited for controlled release and general biocompatibility.
5	**Application Decision**	The choice between nanoparticles and liposomes depends on the drug, disease, required drug profile, and delivery approach. Both have specific advantages tailored to different medical needs.

5.2. Alternative Vesicular Systems: Proniosomes and Effervescent Tablets

Besides liposomes, there are proniosomes and effervescent tablets, which are other vesicular systems being explored for drug delivery. Proniosomes are dry free-flowing powders that, upon hydration, form niosomes, non-ionic surfactant vesicles that, in structure, resemble liposomes but are

 doi:10.20944/preprints202501.1875.v1

based on non-ionic surfactants instead of phospholipids. This makes them potentially cheaper to produce. Some advantages of proniosomes are: they are easy to store, and the size of vesicles is controlled after rehydration [7]. Like liposomes, proniosomes can entrap both hydrophilic and lipophilic drugs for controlled release in topical and transdermal drug delivery applications.

The effervescent tablets, hence, are the solid dosage forms that, upon getting dissolved in water, produce effervescence; it will froth like carbonated drink. This allows the drugs to get dissolved rapidly, leading to rapid drug absorption in the gastrointestinal tract. Effervescent tablets, mainly when used in combination with liposomal formulations, can enhance drug bioavailability and stability, mainly of those water-insoluble drugs [8]. This also masks the unpleasant taste of some drugs, thus making it easier for patients to comply, especially in pediatric and geriatric patients. Although proniosomes and effervescent tablets have some unique advantages over each other, liposomes remain the gold standard in drug delivery due to versatility, safety, and ability to enclose a broad range of therapeutic agents.

6. Herbal Approaches and Liposomal Integration

In an effort to further improve the bioavailability and effectiveness of natural drugs, researchers are increasingly interested in the integration of herbal medicines with liposomal drug delivery systems. Herbal medicines such as Tribulus terrestris, used for long times in traditional medicine, have the potential to offer new opportunities with modern drug delivery systems to help treat a broad spectrum of inflammatory diseases, chronic diseases, and cancer.

6.1. Advances in Herbal Treatments and Liposome Compatibility (Focus on Tribulus terrestris)

Bioavailable the active ingredients are usually in poor solubility and very significant first pass metabolism. Some years back, encapsulation by the use of liposomal formulation may help with the tribulus terrestris, in a medicine used hundreds of years before to protect as medicinal plant: properties anti-inflammatory antioxidant anti - cancerous activity by using of liposomes with protecting compounds degradations while reaching to suitable target.

Recent researches have included the use of liposomes with improved bioavailability and controlled release of extracts of Tribulus terrestris for improving the effectiveness of herbal drugs. In this process, active compounds ensure delivery to the bloodstream through liposomal encapsulation, thus avoiding digestive degradation; instead, it is released over a period for long-term therapeutics [15].

6.2. Applications of Herbal Medicines with Liposomal Formulations for Targeted Delivery

The combination of herbal medicines with the liposomal systems can offer the targeted delivery mechanism, which in itself is highly preferable to the classical forms of formulations of drugs. Indeed, employment of liposomes as carriers of herbal drugs presents an opportunity whereby one increases not only the compounds' stability but also their bioavailability and targets a cell or tissue toward better delivery. For instance, the Tribulus terrestris liposomal formulation could be engineered with surface modification enhancement for PEGylation or attaching targeting ligands that make it possible for herbal medicine to reach specific receptors or tumour cells where the drug will be delivered more targetedly with minimal side effects [14], [15].

The liposomes can be used to combine herbal drugs with other therapeutic agents such as chemotherapeutic agents or anti-inflammatory drugs that, in concert, would produce a synergistic effect. Thus, the absolute oral bioavailability of both herbal and conventional drugs may be improved or both may arrive at their site of action in a much more efficient and controlled manner possibly improving the total therapeutic outcome in treating chronic diseases, cancer, and inflammatory disorders.

 doi:10.20944/preprints202501.1875.v1

7. Challenges and Opportunities

Although liposomal drug delivery systems possess many advantages, challenges remain that have to be addressed to exploit this potential fully. Among them are problems in the scaling-up process, instability, and regulatory issues. Nevertheless, such problems also pose substantial opportunities for further development in the field of liposomal technology.

7.1. Scalability, Stability, and Regulatory Challenges

The scale-up of formulations of liposomes prepared in the laboratory to industrial production is challenging and costly. Concerns of batch-to-batch reproducibility and scaling of the production processes for liposomes while maintaining stability need to be carefully addressed to maintain their efficacy and safety for therapy. For instance, liposomes are characterized by physical instability, such as aggregation or fusion, especially under conditions of high shear forces, heat, or freezing temperatures [11]. Such problems might compromise the effectiveness of drug delivery and shelf life.

Regulatory issues are the other major issue to liposomal formulation. Formulation of drug by liposomes faces a very thorough analysis of its safety, effectiveness, and biocompatibility for regulatory approval as medicines. For all the regulations necessary for application at clinics, EMA, and FDA have well-defined guidelines and criteria for liposome-based medicines, hence long process is involved. Thus, the law must be passed accurately by manufacturers in order for their liposomal formulation to qualify with the regulation required for the clinical usage [16].

7.2. Opportunities for Advancing Liposomal Technology

The challenges do not imply a bleak future. New scientific discoveries in nanotechnology, surface modification, and formulation strategy are refining liposomal technology even further to ensure enhanced effectiveness in their systems. Also, novel targeting delivery includes both active targeting and stimuli-responsive liposomes. Treatment of disease accurately with less adverse effect creates bright prospects and increases the attraction manifold.

This will especially unlock huge potential in the further improvement of the efficacy of liposomal-based therapies using novel technologies in personalized medicine, gene therapy, and biomarkers as targeted drug delivery. As research and development progress, formulators can continue to improve liposomal preparations not only in efficiency but also in terms of cost and versatility to be applicable in various therapeutic fields [9].

8. Conclusion:

Among the promising approaches in the scenario of modern pharmaceutical research and their therapeutic applications is liposomal drug delivery systems. Because of its unique capability of encapsulating drugs both hydrophobic as well as hydrophilic, liposomes have been characterized as versatile carriers in a number of pharmaceutical applications, especially those involving chronic diseases, cancer, and inflammatory disorders. These liposomes are designed over time with more formulation designs discovered, like the use of surface-modified liposomes or more advanced nanotechnology-based personalized targeting strategies related with superior therapeutic efficiency and fewer side effects.

Liposome technology has improved drug delivery significantly with new methods, such as PEGylation, drug encapsulation techniques, and controlled release mechanisms, among others, ensuring therapeutic agents are effectively and selectively delivered. Furthermore, liposomes can be used simply as drug carriers with conventional drugs and herbal drugs, such as the inclusion of extracts of Tribulus terrestris that enhance bioavailability and confer synergistic therapy.

Despite the promising offers, scaling up of liposomal formulations raises challenges in the form of stability and regulatory issues. However, with research being continually done on overcoming the above obstacles, the new technologies promising the future have been stimuli-responsive liposomes, nanotechnology, and bio-marker-guided delivery.

In a nutshell, a liposomal drug delivery system is at the cutting edge of drug development with more efficacy, specificity, and individualization in treatment. Continuing with further research to alter the versatility, safety, and effectiveness of liposomal systems likely expands, thereby becoming a therapy that cannot be replaced in the treatment of several diseases.

References

1. Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. *International Journal of Research Publication and Reviews, 4*(8), 1379–1384. ISSN 2582-7421.
2. Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. *World Journal of Pharmaceutical Research, 13*(13), 1155–1169. https://doi.org/10.20959/wjpr202413-32990
3. Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. *World Journal of Pharmaceutical Research, 13*(13), 1243–1262.
4. Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. *World Journal of Pharmaceutical Research, 13*(13), 1112–1140.
5. Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. *World Journal of Pharmaceutical Research, 13*(16), 176–189.
6. Sengar, A., Yadav, S., & Niranjan, S. K. (2024). Formulation and evaluation of mouth-dissolving films of propranolol hydrochloride. *World Journal of Pharmaceutical Research, 13*(16), 850–861.
7. Sengar, A., Tile, S. A., Sen, A., Malunjkar, S. P., Bhagat, D. T., & Thete, A. K. (2024). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. *World Journal of Pharmaceutical Research, 13*(18), 1424–1435.
8. Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. *World Journal of Pharmaceutical Research, 13*(21), 1063–1071.
9. Sengar, A. (2024). Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. *Preprints.* https://doi.org/10.20944/preprints202412.0019.v1
10. Sengar, A. (2024). Precision in practice: Nanotechnology and targeted therapies for personalized care. *International Journal of Advanced Nano Computing and Analytics, 3*(2), 56–67.
11. Sengar, A. (2025). Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive Introduction. *Preprints.* https://doi.org/10.20944/preprints202501.0206.v1
12. Sengar, A. (2025). Liposomal Drug Delivery Systems: An Intro as a Primer for Advanced Therapeutics. *Preprints.* https://doi.org/10.20944/preprints202501.0398.v1
13. Sengar, A. (2025). Targeting Strategies in Liposomal Drug Delivery. *Preprints.* https://doi.org/10.20944/preprints202501.0866.v1
14. Sengar, A., Chatekar, V. K., Andhare, S. B., & Sharma, L. (2025). Clinical pharmacology of antibiotics: Mechanisms, therapeutic uses, and resistance patterns. *World Journal of Pharmaceutical Research, 14*(1), 1531–1545. https://doi.org/10.20959/wjpr20251-35216
15. Sengar, A., et al. (2025). Advancing urolithiasis treatment through herbal medicine: A focus on *Tribulus terrestris* fruits. *World Journal of Pharmaceutical Research, 14*(2), 91–105.
16. Sengar, A. (2024). Liposomes and beyond: Pioneering vesicular systems for drug delivery. *Preprints.* https://www.preprints.org/manuscript/202412.2230/v1